MetaCap

BioVie (BIVI) vs CalciMedica (CALC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed CalciMedica (CALC) over the past year, losing 38.2% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-38.22%CALC-92.34%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
BIVI-99.86%CALC-94.99%
+41%-33%-107%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus CALC key metrics
MetricBIVICALC
Share price$0.80$1.26
Market cap$8.58M$8.69M
1-day change-12.07%+7.69%
YTD return-31.03%-96.18%
1-year return-38.22%-92.34%
5-year return-99.87%—
EPS (TTM)$-2.85$-4.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.07M$-29.56M
52-week high$3.79$36.00
52-week low$0.7515$1.00
Distance from 52-week high-78.89%-96.50%
Analyst consensusnonenone
Avg. price target upside+557.50%+3868.25%
Average volume568.61K80.15K
Shares outstanding10.72M6.90M
Employees1315
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed CALC by 54.1 percentage points over the past year.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

BIVI vs CALC FAQ

Which is bigger, BioVie or CalciMedica?

CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.58M for BioVie (BIVI).

Which stock has performed better over the past year, BIVI or CALC?

BIVI returned -38.22% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are BioVie and CalciMedica in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons